New Implantable Pump for Long-Term Morphine Infusion Is Introduced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

NORWOOD, Mass--A new implantable pump with an inexhaustible power supply and a constant flow feature may allow lower morphine doses in patients with cancer pain.

NORWOOD, Mass--A new implantable pump with an inexhaustible powersupply and a constant flow feature may allow lower morphine dosesin patients with cancer pain.

Infusaid Model 400, a single catheter implantable pump from Strato/InfusaidInc., a subsidiary of Pfizer Inc., has received FDA approval forthe intrathecal infusion of Infumorph (preservative-free morphine)for treatment of severe and prolonged malignant and nonmalignantpain in patients who do not respond to conventional treatmentregimens.

The constant flow feature allows a continuous low-dose infusionof drug into the epidural or intrathecal space.

The pump is powered by a two-phase charging fluid that liquefieswhen the drug reservoir is filled. The drug is dispensed as thecharging fluid changes to a vapor state. Thus the Infusaid Model400 never needs programming, recharging, or explantation due tobattery depletion, the company said.

Priced at about $5,000, the Infusaid Model 400 may be less expensivethan current alternatives. The manufacturer estimates total treatmentcost at 6 months of about $18,600 with Infusaid, compared to anestimated $21,000 for implantable programmable pumps, $31,000for implanted catheters, and $38,000 for externalized systems.Any such cost advan-tages would increase as patient survival lengthens,the company said. At 4 years, for example, treatment cost withInfusaid would be about $35,000, compared with an estimated $274,000for treatment with an externalized system.

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
4 KOLs are featured in this series.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.